BidaskClub Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold

BidaskClub cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report released on Friday, June 8th.

Other analysts also recently issued research reports about the company. Zacks Investment Research raised Amicus Therapeutics from a sell rating to a hold rating in a research report on Thursday, May 10th. ValuEngine upgraded Amicus Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Cowen reiterated a buy rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. Finally, Leerink Swann boosted their price target on Amicus Therapeutics from $20.00 to $24.00 and gave the company an outperform rating in a research note on Thursday, February 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $19.06.

FOLD stock opened at $16.50 on Friday. The firm has a market cap of $3.08 billion, a P/E ratio of -5.65 and a beta of 1.53. Amicus Therapeutics has a fifty-two week low of $9.47 and a fifty-two week high of $17.40. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32.



Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $16.78 million. equities research analysts expect that Amicus Therapeutics will post -1.26 EPS for the current fiscal year.

In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $14.04, for a total value of $70,200.00. Following the transaction, the insider now owns 90,409 shares in the company, valued at $1,269,342.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Hung Do sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the transaction, the insider now owns 446,771 shares in the company, valued at approximately $6,701,565. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,000 shares of company stock valued at $2,132,800. Company insiders own 2.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Palisade Capital Management LLC NJ bought a new stake in Amicus Therapeutics during the first quarter worth about $211,000. Xact Kapitalforvaltning AB bought a new stake in Amicus Therapeutics during the fourth quarter worth about $219,000. Rockefeller Capital Management L.P. bought a new position in shares of Amicus Therapeutics in the first quarter worth approximately $288,000. WINTON GROUP Ltd bought a new position in shares of Amicus Therapeutics in the first quarter worth approximately $383,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of Amicus Therapeutics in the fourth quarter worth approximately $392,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply